

BUSINESS STANDARD

16TH NOVEMBER, 2018

Business Standard HYDERABAD | FRIDAY, 16 NOVEMBER 2018

COMBAT DRUGS LIMITED

Regd. Off: 4th Floor, Plot No.94, Sagar Society, Rd. No.2, Banjara Hills, Hyderabad - 500034 TS

Works: 9-109/9, P.No.112, Rd No:14, Gayatri Nagar, Bouduppal, Hyderabad-500 039, TS

(CIN NO. CL23230TG1986PLC006781) Ph: 040-48536100, URL: www.combatdrugs.in, Mail: info@combatdrugs.in

EXTRACT OF UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30th SEPTEMBER, 2018
(Amount - Rupees in Lakhs)

Particulars	Standalone						Consolidated			
	Quarter Ended			Half Year Ended		Year Ended	Quarter Ended	Half Year	Year Ended	
	30-09-18	30-06-18	30-09-17	30-09-18	30-09-17	31-03-18	30-09-18	30-06-18	30-09-18	31-03-18
1 Total Income from Operations	133.92	485.60	22.90	619.52	26.49	113.00	133.94	486.26	626.20	113.80
2 Net Profit / (Loss) for the period (before Tax, Exceptional / Extraordinary Items)	11.35	7.41	12.33	18.76	4.55	18.24	9.12	7.94	16.95	18.24
3 Net Profit / (Loss) for the period before tax (after Exceptional / Extraordinary Items)	11.35	7.41	12.33	18.76	4.55	18.24	9.12	7.94	16.95	18.24
4 Net Profit / (Loss) for the period after tax (after Exceptional / Extraordinary Items)	11.35	7.41	12.33	18.76	4.55	18.24	9.12	7.94	16.90	18.24
5 Total Comprehensive Income for the period	11.35	7.41	12.33	18.76	4.55	18.24	9.12	7.94	16.90	18.24
6 Equity Share Capital	800	800	800	800	800	800	800	800	800	800
7 Reserves										
8 Basic & Diluted Earning per Share (of Rs.10/- each)										
Basic:	0.14	0.09	0.15	0.23	0.06	0.23	0.11	0.10	0.21	0.23
Diluted:	0.14	0.09	0.15	0.23	0.06	0.23	0.11	0.10	0.21	0.23

Notes:-

- The above is an extract of the detailed format of Quarterly and Annual Financial Results filed with the stock exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Quarterly Results along with limited Review Report are available on the Stock Exchange Website www.bseindia.com and on Company's website www.combatdrugs.in
- The above Financial Results as recommended by the Audit Committee were considered and approved by the Board of Directors at their meeting held on 14th November, 2018.
- The consolidated results include the figures of the subsidiary RA Labs Pte Ltd and ICP Solutions Pvt Ltd
- The Earnings per Share is calculated on the Net Profit. The Company operates only in a single segment.
- Previous years / period's figures have been regrouped / rearranged / recasted wherever necessary.

Place: Hyderabad
Date: 14.11.2018

By order of the Board
For Combat Drugs Limited
Sd/-
S.M.Lal
Director

NAVATELANGANA
16TH NOVEMBER, 2018

Pharmaids Pharmaceuticals Limited
A-4, 11/232/1-12, Interim High, Hyderabad - 500 035
Email: info@pharmaids.com, pharmaids@pharmaids.com, Website: www.pharmaids.com
CIN No. L22520TG1989PLC03079

EXTRACT OF STATEMENT OF UN-AUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH SEPTEMBER, 2018
(Rs. in Lakhs)

Sl. No.	Particulars	3 Months Ended			Year ended
		30.09.2018	30.09.2017	30.09.2017	31.03.2018
		Un-Audited		Audited	
1	Total Income from Operations	0	0	4.90	44.91
2	Net Profit/(Loss) from Ordinary activities after tax	(9.95)	(3.59)	(8.99)	(38.57)
3	Net Profit/(Loss) for the period after tax (after Extraordinary items)	(9.95)	(3.59)	(8.99)	(38.57)
4	Equity Share Capital of Rs. 10/- each	336.31	336.31	336.31	336.51
5	Reserves excluding Reserves as shown in the Balance Sheet of previous year	9.94	9.94	9.94	9.94
6	Earnings Per Share (before extraordinary items - not annualised)				
	(a) Basic	(9.27)	(8.11)	(8.26)	(1.13)
	(b) Diluted	(9.27)	(8.11)	(8.26)	(1.13)
7	Earnings Per Share (after extraordinary items - not annualised)				
	(a) Basic	(9.27)	(8.11)	(8.26)	(1.13)
	(b) Diluted	(9.27)	(8.11)	(8.26)	(1.13)

Notes: 1) The above results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on 13th November, 2018.
2) The Un-Audited Financial Results for the Quarter 2 and ended 30th September, 2018 have been prepared and reviewed by the Statutory Auditors in pursuance of Schedule III of Companies Act, 2013. 3) The figures of the previous year/periods have been regrouped/re-classified, whenever necessary, for the purpose of comparison. 4) The company operates in a single segment and the results pertain to a single segment, i.e., drug formulation only.

Place: Hyderabad Date: 13.11.2018
Dr. Ghansham Jain Managing Director

SOPHIA TRAEXP LIMITED
CIN: L21000TG1983PLC113227
దిశాస్థాని ఆఫీసు: ప్లాట్ నం.401, డి.కే. రోడ్ నం. 6-3-1086డి, డి.కే. జవహర్, రాజ్ భవన్ లోడ్, హైదరాబాద్, తెలంగాణ రాష్ట్రం
ఫోన్: 040-26000000
30.09.2018లో మూల్యం ప్రకటించిన సందర్భం కోసం: కొరత ఉంటే దీనిని ఇతర పరిశాల పాఠాంశం (జీఎస్ టీఎస్) ఉపయోగించండి

Sl. No.	వివరాలు	30.09.2018లో మూల్యం ప్రకటించిన అధికారము	30.09.2018లో మూల్యం అధికారము	30.09.2017లో మూల్యం ప్రకటించిన అధికారము
1	ఇంటర్మీడియట్ ఫ్యాకల్టీ అధికారం (10వ తరగతి) కార్యకర్తలలో నిజం లాభం/నష్టం (సంపూర్ణ) (సంపూర్ణ) (మొదటి సారి) మరియు/లేదా అపారాధం అధికారం	5.94	16.09	3.59
2	మొదటి సారి మరియు/లేదా అపారాధం అధికారం	(2.13)	(1.51)	0.11
3	మొదటి సారి మరియు/లేదా అపారాధం అధికారం	(2.13)	(1.51)	0.11
4	మొదటి సారి మరియు/లేదా అపారాధం అధికారం	(2.13)	(1.51)	0.11
5	మొదటి సారి మరియు/లేదా అపారాధం అధికారం	510.00	510.00	20.00
6	మొదటి సారి మరియు/లేదా అపారాధం అధికారం	(0.04)	-0.03	0.06
7	మొదటి సారి మరియు/లేదా అపారాధం అధికారం	(0.04)	-0.03	0.06

గమనిక: 1. పేజీ (టిస్సీ) అండ్ అదర్ డివైజ్ అండ్ రిజిస్ట్రేషన్, 2015 యొక్క రిగ్యులేషన్ 33 క్రింద స్టాక్ మార్కెట్లో దాఖలు చేయబడిన ప్రమాణిక/దాఖల అధిక పరిశాల వివరణాత్మక ఫార్మాట్ యొక్క పాఠాంశం ప్రకటించబడినది. ప్రమాణిక/దాఖల అధిక పరిశాల ఫార్మాట్ స్టాక్ మార్కెట్లో పేజీ అధికారం, డివైజ్ టిఎస్. www.bseindia.com వద్ద మరియు కంపెనీ యొక్క వెబ్సైట్ పై అందుబాటులో ఉంటాయి.

For Sophia Traexpo Limited
సం/-
ప్ర. మధ్యస్థానం రాష్ట్రం
ఫోన్: 040-26000000
DIN:00905266

COMBAT DRUGS LIMITED
Regd. Off: 4th Floor, Plot No.94, Sagar Society, Rd. No.2, Banjara Hills, Hyderabad - 500034 TS
Works: 9-109/9, P.No.112, Rd No 14, Gayatri Nagar, Bouduppall, Hyderabad-500 039, TS
(CIN NO. CL23230TG1986PLC006781) Ph: 040-48536100, URL: www.combatdrugs.in, Mail: info@combatdrugs.in

EXTRACT OF UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH SEPTEMBER, 2018
(Amount - Rupees in Lakhs)

Particulars	Standalone			Consolidated		
	Quarter Ended	Half Year Ended	Year Ended	Quarter Ended	Half Year	Year Ended
	30-09-18	30-06-18	30-09-17	30-09-18	30-06-18	31-03-18
1 Total Income from Operations	133.92	465.80	22.90	818.52	28.48	113.00
2 Net Profit / (Loss) for the period (before Tax, Exceptional / Extraordinary items)	11.35	7.41	12.33	18.76	4.55	18.24
3 Net Profit / (Loss) for the period before tax (after Exceptional / Extraordinary items)	11.35	7.41	12.33	18.76	4.55	18.24
4 Net Profit / (Loss) for the period after tax (after Exceptional / Extraordinary items)	11.35	7.41	12.33	18.76	4.55	18.24
5 Total Comprehensive Income for the period	11.35	7.41	12.33	18.76	4.55	18.24
6 Equity Share Capital	800	800	800	800	800	800
7 Reserves	800	800	800	800	800	800
8 Basic & Diluted Earning per Share (of Rs.10/- each)						
Basic:	0.14	0.09	0.15	0.23	0.08	0.23
Diluted:	0.14	0.09	0.15	0.23	0.08	0.23

Notes:
1. The above is an extract of the detailed format of Quarterly and Annual Financial Results filed with the stock exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Quarterly Results along with limited Review Report are available on the Stock Exchange Website www.bseindia.com and on Companies website www.combatdrugs.in
2. The above Financial Results as recommended by the Audit Committee were considered and approved by the Board of Directors at their meeting held on 14th November, 2018.
3. The consolidated results include the figures of the subsidiary RA Labs Pte Ltd and ICP Solutions Pvt Ltd
4. The Earnings per Share is calculated on the Net Profit. The Company operates only in a single segment.
5. Previous years / period's figures have been regrouped / rearranged / recasted wherever necessary.

Place: Hyderabad Date: 14.11.2018
By Order of the Board For Combat Drugs Limited
S.M.Lal Director

SPACENET ENTERPRISES INDIA LIMITED
(formerly Northgate Com Tech Limited)
CIN : L72200TG2010PLC068624